Synthetic Biology introduces NanoSyrinx

▴ nanosyrinx-s-initial-focus-development-ex-vivo-gene-editing-nanosyringe-concept
Synthetic Biology start up NanoSyrinx secures capital to develop its fully customisable platform for intra-cellular engineering

NanoSyrinx an emerging biotechnology company developing new therapeutic modalities for Cell & Gene editing announced the closing of Pre-Seed financing led by M Ventures, the corporate venture capital arm of Merck. BioCity (Nottingham, United Kingdom) and UK Innovation & Science Seed Fund (UKI2S) (Oxford, United Kingdom) also participated in the financing. The company also secured grant funding from the UKI2S Innovate Accelerator and Midlands Innovation Commercialisation of Research Accelerator (MICRA) recently.

NanoSyrinx is developing a fully customisable genetic platform that selectively delivers peptide and protein payloads – including functional gene-editing enzymes and nucleases – directly to the cytosol of targeted cells. The system was first identified by the Waterfield Lab based at Warwick Medical School at the University of Warwick. NanoSyrinx Ltd was founded in 2020 following the completion of an extensive international market validation exercise under the ICURe programme, funded by Innovate UK. The platform developed by the team offers a unique combination of features, overcoming challenges such as payload limitations and manufacturing complexities, which has limited the adoption of other intracellular delivery approaches.

CEO Dr Joe Healey, who joined from the Waterfield Lab to lead the company, said, “We believe that our nanosyringe platform will unlock new approaches for the treatment of many intractable diseases and will be of value to a wide range of potential partners and customers. The company is delighted with the early progress made in both in vivo active pharmaceutical delivery and ex vivo cell engineering applications.”

NanoSyrinx’s initial focus will be on the development of its ex vivo gene editing nanosyringe concept, having already engaged with a number of leaders in the cell therapy field.

Dr Arnaud Autret, Investment Principal at M Ventures, who joined the Board, said, "The platform technology underpinning NanoSyrinx has major potential value across a range of Life Sciences areas. We are excited to be part of the venture at this early stage and to help shape a successful future. The team has done excellent work to develop and secure the technology which provides a strong basis for growth. The company’s strong technical foundations will be attractive to new investment partners when it seeks its next equity financing round in Q1 2021 to further support its development."

Tags : #SyntheticBiology #NanoSyrinx #DrJoeHealey #DrArnaudAutret

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Daily Covid-19 cases in US will hit six digits soon, warns expertsOctober 24, 2020
ICMR backed Covaxin could be ready by June 2021 ; Bharat BiotechOctober 24, 2020
Sewage signals early warning of coronavirus outbreaksOctober 24, 2020
U.S. sets single-day record for COVID-19 cases during new surgeOctober 24, 2020
Expert finds limited effectiveness of convalescent plasma for covid-19 patientsOctober 24, 2020
87 year old homeopathic doctor provides home visits to COVID-19 patients in Chandrapur district of MaharashtraOctober 24, 2020
Steroids boost survival of preterm babies in low-resource settings, new study findsOctober 24, 2020
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic CancerOctober 24, 2020
FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trialOctober 24, 2020
New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological CancersOctober 24, 2020
PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine CandidateOctober 24, 2020
Gujarat records 1112 new cases of COVID-19 in last 24 hoursOctober 24, 2020
2377 COVID-19 patients recovered in Odisha in last 24 hoursOctober 24, 2020
Over 70 lakh people recovered from COVID-19 infection in country so farOctober 24, 2020
Health Minister Harsh Vardhan says next three months are crucial for country in fight against COVID-19October 24, 2020
Pfizer's Hospital Business section acquires Arixa Pharma October 24, 2020
India crosses the landmark of 10 crore total testsOctober 24, 2020
Bharat Biotech to conduct Phase 3 Trials Of Covaxin On 26,000 people across 25 sitesOctober 24, 2020
Catalent launches OptiGel DR, a delayed/enteric release Softgel October 24, 2020
Health Protection Campaign to be launched soon in ChhattisgarhOctober 24, 2020